Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4297911

SPESOLIMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL4297911
Name SPESOLIMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

BI 655130 BI-655130 Bi655130 Espesolimab Spesolimab Spesolimab sbzo Spesolimab-sbzo Spevigo
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
8
Known Names
9
Indications
1
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2022
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral

Flags

First in Class
USAN Stem -mab
USAN Year 2021

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
IL36 receptor antagonist ANTAGONIST IL36 receptor ✓ ✓

Indications

Immune System Diseases Psoriasis Psoriasis Colitis, Ulcerative Crohn Disease Hidradenitis Suppurativa Netherton Syndrome Pyoderma Inflammation

ATC Classification

L04AC22
spesolimab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: IMMUNOSUPPRESSANTS

Data from ChEMBL 36 via Core Engine